| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| H2017 |
Psychosocial rehabilitation services, per 15 minutes |
14,975 |
1,215 |
$1.52M |
| T1017 |
Targeted case management, each 15 minutes |
1,738 |
246 |
$137K |
| T1015 |
Clinic visit/encounter, all-inclusive |
554 |
524 |
$12K |
| H2000 |
Comprehensive multidisciplinary evaluation |
59 |
54 |
$8K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
210 |
92 |
$8K |
| H0032 |
Mental health service plan development by non-physician |
79 |
68 |
$7K |
| M0243 |
Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring |
16 |
16 |
$4K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
40 |
40 |
$2K |
| H0031 |
Mental health assessment, by non-physician |
157 |
80 |
$2K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
15 |
15 |
$2K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
267 |
65 |
$1K |
| H2019 |
Therapeutic behavioral services, per 15 minutes |
26 |
16 |
$940.96 |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
367 |
81 |
$760.00 |
| G0108 |
Diabetes outpatient self-management training services, individual, per 30 minutes |
12 |
12 |
$634.56 |
| 99402 |
|
152 |
37 |
$252.96 |
| 99205 |
Prolong outpt/office vis |
74 |
15 |
$140.89 |
| 93000 |
|
13 |
13 |
$139.09 |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
41 |
15 |
$0.00 |
| M0220 |
Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring |
357 |
87 |
$0.00 |
| 99404 |
|
74 |
16 |
$0.00 |